targeted oncology
News/ News/ News/ Oncology/ Sales and Marketing
AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy
Phil Taylor
adjuvant, AstraZeneca, breast cancer, EU, Lynparza, Merck & Co, Oncology, targeted oncology
0 Comment
News/ News/ News/ Oncology/ Sales and Marketing
FDA clears new first-line use for Servier’s Tibsovo in AML
Phil Taylor
acute myeloid leukaemia, Oncology, Servier, targeted oncology, Tibsovo
0 Comment
AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy
Phil Taylor
AstraZeneca, BRCA, breast cancer, Merck & Co, Oncology, PARP inhibitor, regulatory approval, targeted oncology
0 Comment
Amgen grabs EU approval for pathfinder KRAS drug Lumykras
Phil Taylor
Amgen, KRAS, Lumakras, Lumykras, Non-small cell lung cancer, Oncology, targeted oncology
0 Comment
ASH: Servier’s Tibsovo poised for first-line used in AML
Phil Taylor
acute myeloid leukaemia, Oncology, Servier, targeted oncology, Tibsovo
0 Comment
Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval
Phil Taylor
EGFR, Exkivity, fda, NSCLC, Oncology, regulatory approval, Takeda, targeted oncology
0 Comment
Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal
Phil Taylor
acute myeloid leukaemia, Agios, haemotology, Oncology, Servier, targeted oncology
0 Comment
NICE changes its mind on rare bile duct cancer drug from Incyte
Phil Taylor
cholangiocarcinoma, HEOR, Incyte, NICE, Oncology, Pemazyre, pemigatinib, targeted oncology
0 Comment